

(19)



(11)

EP 1 800 693 A1

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:

27.06.2007 Bulletin 2007/26

(51) Int Cl.:

A61K 39/395 (2006.01)

A61P 35/00 (2006.01)

(21) Application number: 05780979.0

(86) International application number:

PCT/JP2005/015607

(22) Date of filing: 23.08.2005

(87) International publication number:

WO 2006/022407 (02.03.2006 Gazette 2006/09)

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI  
SK TR

• SUGIMOTO, Masamichi

Kamakura-shi Kanagawa 2478530 (JP)

• OKABE, Hisafumi

Kamakura-shi Kanagawa 2478530 (JP)

(30) Priority: 24.08.2004 JP 2004244273

28.03.2005 JP 2005090945

(74) Representative: Woods, Geoffrey Corlett

J.A. KEMP & CO.

Gray's Inn

14 South Square

London WC1R 5JJ (GB)

(71) Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA  
Tokyo, 115-8543 (JP)

(72) Inventors:


• KINOSHITA, Yasuko

Kamakura-shi Kanagawa 2478530 (JP)

**(54) ADJUVANT THERAPY WITH THE USE OF ANTI-GLYPLICAN 3 ANTIBODY**

(57) The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment. Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-

cancer agent according to the present invention is preferably administered if glypican 3 is expressed in the resected liver cancer cells. The anti-glypican 3 antibody is preferably a monoclonal antibody. The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.



**FIG. 1**

**Description****TECHNICAL FIELD**

5 [0001] The present invention relates to adjuvant therapy following a cancer treatment, in which the adjuvant therapy utilizes anti-glypican 3 antibody.

**BACKGROUND ART**

10 [0002] The glypican family has been reported to be a novel family of heparan sulfate proteoglycans present on the cell surface. Five species of glypicans (glypican 1, glypican 2, glypican 3, glypican 4, and glypican 5) have been reported as members of the glypican family to date. The members of this family have a core protein of uniform size (approximately 60 kDa), share a unique and highly conserved sequence of cysteines, and are bound to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor.

15 [0003] Dally (division abnormally delayed) gene was identified by genetic screening of *Drosophila melanogaster* mutants that had an abnormal cell division pattern during the development of central nervous system. cDNA of Dally has been shown to have an open reading frame (ORF) that codes for a product that exhibits sequence homology (24 to 26% homology) with vertebrate integral membrane proteoglycans (GRIPs) having all the characteristics of glypicans. It was later suggested that Dally plays a role in regulating the dpp (decapentaplegia) receptor mechanism, suggesting 20 the possibility that mammalian glypican modulates TGF and BMP signal transduction. That is, it has been suggested that glypican may function as a coreceptor for some heparin-binding growth factors (e.g., EGF, PDGF, BMP2, FGFs).

25 [0004] Glypican 3 was isolated as a developmentally regulated transcript from the rat small intestine (Filmus, J., Church, J.G., and Buick, R.N. (1988) Mol. Cell. Biol. 8, 4243-4249). It was thereafter identified as OCI-5, a GPI anchored type heparan sulfate proteoglycan of the glypican family having a core protein with a molecular weight of 69 kDa (Filmus, J., Shi, W., Wong, Z.-M., and Wong, M.J. (1995) Biochem. J. 311, 561-565). In humans, a gene encoding glypican 3 has also been isolated as MRX-7 from a human stomach cancer cell line (Hermann Lage et al., Gene 188 (1997) 151-156). Glypican 3 has been reported to form a protein-protein complex with insulin-like growth factor-2 and to regulate the action of this growth factor (Pilia, G. et al. (1996) Nat. Genet. 12, 241-247). This report suggests that glypican 3 does not necessarily interact with growth factors through the heparan sulfate chain.

30 [0005] It has also been reported that glypican 3 may possibly be utilized as a marker of hepatocellular carcinoma (Hey-Chi Hsu et al., Cancer Research 57, 5179-5184 (1997)). Also it has been reported that anti-glypican 3 antibody exhibits a cytotoxic activity against liver cancer cells and may be useful as an anti-cancer agent (WO 03/00883).

35 [0006] However, there have been no reports to the effect that it is possible to use anti-glypican 3 antibody for adjuvant therapy after a cancer treatment.

**SUMMARY OF THE INVENTION**

40 [0007] As a result of extensive and intensive investigations, the present inventors discovered that anti-glypican 3 antibody is useful for an adjuvant therapy following a cancer treatment and achieved this invention based on this discovery. In addition, they found that the recurrence of cancer can be prevented by the administration of anti-glypican 3 antibody at a stage after cancer treatment where cancer cells are not observed, and that anti-glypican 3 antibody is useful as an agent for preventing cancer and as an agent for preventing the recurrence of cancer.

**BRIEF DESCRIPTION OF THE DRAWINGS**

45 [0008]

Figure 1 is a graph showing the effect of the anti-cancer agent according to the present invention when administered to an intrahepatically transplanted mouse model.

50 Figure 2 is a graph showing the effect of the anticancer agent according to the present invention when administered at an early stage to an intrahepatically transplanted mouse model.

**DETAILED DESCRIPTION OF THE INVENTION**

55 [0009] The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the agent is administered after cancer treatment. After cancer treatment is preferably after the treatment of liver cancer. In particular the treatment of liver cancer is the resection of liver cancer cells. The anti-cancer agent according to the present invention is preferably administered in those cases where glypican 3 is expressed in the resected liver cancer cells. The anti-

glypican 3 antibody is preferably a monoclonal antibody.

**[0010]** The anti-cancer agent according to the present invention is particularly useful in adjuvant therapy. Even in cases where it is believed that cancer treatment surgery has resulted in the removal of the cancer cells or their death, undetected cancer cells may still remain present. Cancer may recur after a certain period of time when such cancer cells remain present, and cancer treatment must therefore be followed by a treatment to prevent cancer recurrence. Such a treatment is known as adjuvant therapy or post-surgical adjuvant therapy.

**[0011]** Within the context of the present invention, cancer treatment refers to any treatment that has a goal including inhibiting the growth of cancer cells or killing cancer cells or decreasing cancer cells, such as resection of the cancer, chemotherapy using an anti-cancer agent, radiation therapy, percutaneous ethanol injection therapy, percutaneous radiofrequency thermal coagulation therapy, or transcatheter arterial embolization therapy. A preferred cancer treatment in the present invention is cancer resection. The concept of "post-cancer treatment" or "after cancer treatment" refers to after such treatments have been carried out. This concept of "post-cancer treatment" or "after cancer treatment" in the present invention does not necessarily mean that the cancer has been cured.

**[0012]** The anti-glypican 3 antibody according to the present invention may be administered to a post-cancer treatment patient after determining as to whether glypican 3 is expressed. Any method may be used to determine whether glypican 3 is being expressed. For example, the expression of glypican 3 protein can be determined using anti-glypican 3 antibody, while the expression of the glypican 3 gene can be determined by, for example, PCR.

**[0013]** The anti-glypican 3 antibody may be administered in any timing after cancer treatment, and administration may be carried out immediately after cancer treatment or after some interval of time. A preferred timing for administration in the present invention is in the interval from after cancer treatment up through cancer recurrence. In the case of post-surgical adjuvant therapy, administration is typically begun within 12 weeks or within 6 weeks after treatment. Recurrence of cancer can be diagnosed by methods known to those skilled in the art; for example, the occurrence of a tumor can be determined by visual findings or by pathological findings. The presence of a tumor can be confirmed by methods known to those skilled in the art, such as imaging or methods based on a tumor marker such as AFP.

**[0014]** Any cancer can be treated using the anti-cancer agent according to the present invention, including, but not limited to, liver cancer, lung cancer, colon cancer, breast cancer, prostate cancer, leukemia, lymphoma, pancreatic cancer, and bile duct cancer. Hepatocarcinoma is a cancer particularly well suited for treatment using the anti-cancer agent according to the present invention. The liver cancer may be primary or secondary cancer, which includes hepatocellular carcinoma, intrahepatic cholangiocarcinoma, bile duct cystadenocarcinoma, combined hepatocellular carcinoma and cholangiocarcinoma, hepatoblastoma, undifferentiated carcinoma, angiosarcoma, leiomyosarcoma of the liver, and undifferentiated sarcoma.

**[0015]** A particularly preferred embodiment of adjuvant therapy using the anti-cancer agent according to the present invention is the prevention of the recurrence of liver cancer by administering anti-glypican 3 antibody after the resection of liver cancer cells.

**[0016]** There are no particular requirements with regard to the origin, type (monoclonal or polyclonal), and form of the anti-glypican 3 antibody used in the present invention.

**[0017]** The anti-glypican 3 antibody used in the present invention can be obtained by a known means in the form of polyclonal or monoclonal antibody. Monoclonal antibody of mammalian origin is a particularly preferred anti-glypican 3 antibody for use in the present invention. Examples of monoclonal antibody of mammalian origin include antibody produced by hybridomas and antibody produced by a host that has been transformed by genetic engineering techniques with an expression vector containing the antibody gene.

**[0018]** A monoclonal antibody-producing hybridoma can be prepared substantially using known techniques as follows. A hybridoma can be prepared by immunization of an animal according to a standard immunization method using glypican 3 as the sensitizing antigen; fusing the resulting immunocytes with known partner cells by a standard cell fusion technique; and then screening for monoclonal antibody-producing cells by a standard screening procedure.

**[0019]** In specific terms, monoclonal antibody can be prepared as follows. First, human glypican 3 for use as the sensitizing antigen for antibody production is obtained by inducing the expression of the glypican 3 (MXR7) according to the gene/amino acid sequence as disclosed by Lage, H. et al., Gene 188 (1997), 151-156. The gene sequence and amino acid sequence of glypican 3 are shown, respectively, in SEQ ID NO: 1 and SEQ ID NO: 2. Specifically, the gene sequence encoding glypican 3 is inserted in a known expression vector system; an appropriate host cell is transformed; and human glypican 3 protein of interest is subsequently purified by a known method from the host cell or the culture supernatant.

**[0020]** This purified glypican 3 protein is then used as the sensitizing antigen. Alternatively, a partial peptide of glypican 3 can be used as the sensitizing antigen. Such a partial peptide can be obtained by chemical synthesis of a peptide in accordance with the amino acid sequence of human glypican 3.

**[0021]** The anti-glypican 3 antibody will exhibit an anti-cancer activity through its cytotoxic activity such as ADCC or CDC. Also it will exhibit an anti-cancer activity by conjugating anti-glypican 3 antibody with a cytotoxic substance such as a radioisotope, a chemotherapeutic agent, or a bacteria-derived toxin. The epitope on the glypican 3 molecule that

is recognized by the anti-glypican 3 antibody is not limited to a particular epitope. The anti-glypican 3 antibody may recognize any epitope that is present on the glypican 3 molecule. Accordingly, any peptide fragment containing an epitope present on the glypican 3 molecule can be used as the antigen for preparing the anti-glypican 3 antibody of the present invention.

5 [0022] The mammal to be immunized with the sensitizing antigen is not specifically limited and is preferably selected based on a consideration of the compatibility with the partner cell that will be used for cell fusion. For example, rabbits, monkeys, or rodents such as mice, rats, and hamsters are generally used.

10 [0023] The animal is immunized with the sensitizing antigen according to known techniques. For example, immunization can be carried out by a general method in which a mammal is injected intraperitoneally or subcutaneously with the sensitizing antigen. Specifically, the sensitizing antigen is diluted with or suspended in an appropriate volume of phosphate-buffered saline (PBS), physiological saline, or the like; an appropriate amount of a standard adjuvant such as Freund's complete adjuvant is admixed therewith as necessary; and the mixture is emulsified and administered to the mammal for a plurality of times every 4 to 21 days. In addition, an appropriate carrier may also be used during immunization with the sensitizing antigen.

15 [0024] A mammalian myeloma cell is used as the partner cell for fusion with the aforementioned immunocyte. Various known cell lines are suitably used as a myeloma cell, and include, for example, P3 (P3x63Ag8.653) (J. Immunol. (1979) 123, 1548-1550), P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81, 1-7), NS-1 (Kohler, G. and Milstein, C. Eur. J. Immunol. (1976) 6, 511-519), MPC-11 (Margulies, D. H. et al., Cell (1976) 8, 405-415), SP2/0 (Shulman, M. et al., Nature (1978) 276, 269-270), FO (de St. Groth, S. F. et al., J. Immunol. Methods (1980) 35, 1-21), S194 (Trowbridge, I. S. J. Exp. Med. (1978) 148, 313-323), and R210 (Galfre, G. et al., Nature (1979) 277, 131-133).

20 [0025] Immunocytes are fused with the myeloma cells substantially according to known procedures, for example, the procedure of Kohler and Milstein et al. (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46).

25 [0026] More specifically, cell fusion is carried out in a standard nutrient culture medium in the presence of, for example, a cell-fusion promoter. For example, polyethylene glycol (PEG), Sendai virus (also known as hemagglutinating virus of Japan or HVJ), or the like may be used as the cell-fusion promoter. If desired, an auxiliary such as dimethyl sulfoxide can also be added in order to further enhance the fusion efficiency.

30 [0027] The immunocytes and myeloma cells may be mixed in any proportion. For example, it is preferable that the number of immunocytes be 1 to 10 times the number of myeloma cells. Examples of the culture medium used for the cell include, for example, RPMI1640 culture medium or MEM culture medium, which are particularly suitable for the growth of the aforementioned myeloma cell lines, and other standard culture media that are used to culture cells of this type. Also a serum supplement such as fetal calf serum (FCS) can be used in combination.

35 [0028] Cell fusion is carried out by thoroughly mixing prescribed amounts of the aforementioned immunocytes and myeloma cells in the aforementioned culture medium; adding a PEG (e.g., with an average molecular weight of approximately 1000 to 6000) solution with a concentration generally of 30 to 60% (w/v) that has been pre-heated to approximately 37 °C; and then mixing them to allow for formation of fused cells (hybridomas) of interest. Subsequently, a suitable medium is added and centrifuged to remove the supernatant. This process is repeated to remove the cell fusion agent and other materials unfavorable to the growth of the hybridoma.

40 [0029] The thus obtained hybridomas are then selected by culturing them in a standard selection culture medium such as HAT culture medium (culture medium containing hypoxanthine, aminopterin, and thymidine). Culture in this HAT culture medium is continued for a time period sufficient for cells (unfused cells) other than the desired hybridomas to die (normally several days to several weeks). A standard limiting dilution procedure is then carried out for screening and monocloning of the hybridoma that produces the desired antibody.

45 [0030] In addition to the aforementioned method of obtaining a hybridoma by immunizing a non-human animal with antigen, the desired human antibodies that exhibit a binding activity for glypican 3 can also be obtained by sensitizing human lymphocytes to glypican 3 in vitro and fusing the sensitized lymphocytes with human-derived myeloma cells that have a permanent division capacity (see Japanese Patent Publication No. Hei 1-59878). In addition, glypican 3 can be administered as an antigen to a transgenic animal having the complete repertoire of human antibody genes; anti-glypican 3 antibody-producing cells can subsequently be obtained; and human antibody against glypican 3 can be obtained from cells produced by immortalizing the anti-glypican 3 antibody-producing cells (see International Patent Publication Nos. 50 WO 94/25585, WO 93/12227, WO 92/03918, and WO 94/02602).

55 [0031] The thus prepared monoclonal antibody-producing hybridoma can be serially cultured on a standard culture medium or can be stored long-term in liquid nitrogen.

[0032] Monoclonal antibodies can be obtained from the hybridoma by, for example, culturing the hybridoma by a standard method and recovering the monoclonal antibodies from the culture supernatant, or administrating and growing the hybridoma in a mammal compatible with the hybridoma and obtaining the monoclonal antibodies from the ascites fluid. The former method is suitable for obtaining antibody of high purity, while the latter method is suitable for the mass production of antibody.

[0033] The monoclonal antibody used in the present invention may be a recombinant monoclonal antibody prepared

by genetic engineering techniques by cloning the antibody gene from the hybridoma, integrating the gene into an appropriate vector, introducing the vector into a host, and causing the host to produce the recombinant monoclonal antibody (e.g., see Vandamme, A. M. et al., *Eur. J. Biochem.* (1990) 192, 767-775, 1990).

[0034] Specifically, mRNA encoding the variable (V) region of an anti-glypican 3 antibody is isolated from a hybridoma that produces anti-glypican 3 antibody. The mRNA can be isolated by a known method, for example, by preparation of the total RNA by the guanidine ultracentrifugation method ( Chirgwin, J. M. et al., *Biochemistry* (1979) 18, 5294-5299) or the AGPC method (Chomczynski, P. et al., *Anal. Biochem.* (1987) 162, 156-159), followed by preparation of the mRNA of interest using mRNA Purification Kit (Pharmacia) or the like. In addition, the mRNA can also be directly prepared using a QuickPrep mRNA Purification Kit (Pharmacia).

[0035] The cDNA of the antibody V region is synthesized from the thus obtained mRNA using reverse transcriptase. cDNA synthesis can be carried out using, for example, an AMV Reverse Transcriptase First-Strand cDNA Synthesis Kit (Seikagaku Corporation) or the like. cDNA synthesis and amplification can also be carried out, for example, by the 5'-RACE method using a 5'-Ampli FINDER RACE Kit (Clontech) and PCR (Frohman, M. A. et al., *Proc. Natl. Acad. Sci. USA* (1988) 85, 8998-9002, Belyavsky, A. et al., *Nucleic Acids Res.* (1989) 17, 2919-2932).

[0036] The target DNA fragment is purified from the thus obtained PCR product and then ligated into a vector DNA to prepare a recombinant vector. The vector is then introduced into, for example, *E. coli*; and colony selection yields the desired recombinant vector. The nucleotide sequence of the target DNA is then determined by a known method, such as the dideoxynucleotide chain termination method.

[0037] After the DNA encoding the V region of the target anti-glypican 3 antibody has been obtained, this DNA is integrated into an expression vector that contains DNA encoding the constant region (C region) of the desired antibody.

[0038] To produce the anti-glypican 3 antibody for use in the present invention, the antibody gene is integrated into an expression vector in such a manner that the gene is expressed under the control of an expression control region, for example, an enhancer and a promoter. Next, a host cell is transformed with the expression vector and expression of the antibody is induced.

[0039] The antibody gene can be expressed by integrating DNA encoding the antibody heavy chain (H-chain) and DNA encoding the antibody light chain (L-chain) separately into expression vectors and then simultaneously transforming a host cell with these vectors; or by integrating DNAs encoding the H-chain and the L-chain into a single expression vector and transforming a host cell with this vector (see WO 94/11523).

[0040] In addition to a host cell as described above, a transgenic animal can be used to produce recombinant antibody. For example, a fused gene can be prepared by inserting the antibody gene into a gene encoding a protein (e.g., goat  $\beta$ -casein) that will be produced in milk. A DNA fragment containing the fused gene with the inserted antibody gene is then injected into a goat embryo and the embryo is introduced into a female goat. The desired antibody can be obtained from the milk produced by the transgenic goat (or its progeny) born from the goat that has received the embryo. Furthermore, suitable hormones can be administered to the transgenic goat in order to increase the volume of milk produced by the transgenic goat that contains the desired antibody (Ebert, K. M. et al., *Bio/Technology* (1994) 12, 699-702).

[0041] In addition to the antibodies cited above, the present invention can make use of artificially modified genetically recombinant antibodies, such as chimeric antibodies and humanized antibodies, for the purpose of lowering the heteroantigenicity for humans. These modified antibodies can be produced by already known methods.

[0042] Chimeric antibodies can be obtained by ligating DNA encoding the antibody V region (obtained as described above) to DNA encoding the human antibody C region, integrating the product into an expression vector, and then introducing the vector into a host and inducing production. Chimeric antibodies useful for the present invention can be obtained by such already known methods.

[0043] Humanized antibodies, which are also referred to as reshaped human antibodies, are prepared by grafting an antibody complementarity determining region (CDR) from a non-human mammal, such as mouse, into the complementarity determining region of a human antibody. General gene recombination techniques for this procedure are also known in the art (see EP 125023 and WO 96/02576).

[0044] Specifically, a DNA sequence designed to link the CDR of a mouse antibody with the framework region (FR) of a human antibody is synthesized by PCR using as primers several oligonucleotides constructed to have regions that overlap the terminal regions of both the CDR and FR (see the method described in WO 98/13388).

[0045] A framework region in which the complementarity determining region forms an excellent antigen-binding site is selected for the human antibody framework region linked with the CDR regions. Amino acids in the framework region in the antibody variable region may be substituted as necessary in order that the complementarity determining region of the reshaped human antibody will form an appropriate antigen-binding site (Sato, K. et al., *Cancer Res.* (1993) 53, 851-856).

[0046] Human antibody C regions are used for the C regions of chimeric antibodies and humanized antibodies. For example, Cy1, Cy2, Cy3, and Cy4 can be used for the H-chain and C $\kappa$  and C $\lambda$  can be used for the L-chain. In addition, the human antibody C region may be modified in order to improve the stability of the antibody or its production process.

[0047] A chimeric antibody consists of the variable region of an antibody derived from a non-human mammal and a

constant region derived from a human antibody, while a humanized antibody consists of a complementarity determining region of an antibody derived from a non-human mammal and a framework region and C region derived from a human antibody. Since the humanized antibody is designed to have a low antigenicity in humans, it is useful as an active ingredient in the therapeutic agent according to the present invention.

5 [0048] The antibody used in the present invention is not limited to the whole antibody molecule as long as it can bind to glycan 3 and inhibit the activity of glycan 3, and therefore encompasses antibody fragments and modifications thereof as well as divalent antibodies and monovalent antibodies. Examples of antibody fragments include Fab, F(ab')  
2, Fv, Fab/c having one Fab and a complete Fc, and single chain Fv (scFv) in which H-chain or L-chain Fv is linked by an appropriate linker. Specifically, an antibody fragment can be produced by treating an antibody with an enzyme such as papain or pepsin. Alternatively, a gene encoding such an antibody fragment can be constructed and introduced into expression vectors and expressed by appropriate host cells (see e.g., Co, M.S. et al., *J. Immunol.* (1994) 152, 2968-2976, Better, M. & Horwitz, A. H. *Methods in Enzymology* (1989) 178, 476-496, Academic Press, Inc., Plueckthun, A. & Skerra, A. *Methods in Enzymology* (1989) 178, 476-496, Academic Press, Inc., Lamoyi, E., *Methods in Enzymology* (1989) 121, 652-663, Rousseaux, J. et al., *Methods in Enzymology* (1989) 121, 663-669, and Bird, R. E. et al., *TIBTECH* (1991) 9, 132-137).

10 [0049] scFv is obtained by linking an antibody H-chain V region and L-chain V region. The H-chain V region and the L-chain V region are linked in scFv through a linker and preferably a peptide linker (Huston, J. S. et al., *Proc. Natl. Acad. Sci. U.S.A.* (1988) 85, 5879-5883). The H-chain V region and the L-chain V region of scFv may be derived from any of the antibodies described herein. The peptide linker linking the V regions can be, for example, any single-stranded peptide comprising 12 to 19 amino acid residues.

15 [0050] DNA encoding scFv can be obtained as follows. DNA encoding the H-chain or H-chain V region of the aforementioned antibody and DNA encoding the L-chain or L-chain V region are amplified by PCR using as templates DNA regions that encode all or desired amino acid sequences of the aforementioned sequences and primer pairs that specify both ends thereof. Then additional amplification is carried out with a combination of DNA encoding a peptide linker region and a primer pair that defines both ends to be ligated to the H-chain and L-chain.

20 [0051] In addition, once scFv-encoding DNA has been prepared, an expression vector containing this DNA and a host transformed with the expression vector can be obtained according to standard methods. The scFv can then be obtained by standard methods using such a host.

25 [0052] An antibody fragment can be produced by preparing a gene coding for the fragment and expressing it in a host in the same manner as described above. The term "antibody" as used herein also encompasses these antibody fragments.

30 [0053] Another example of a modified antibody used in the invention is anti-glycan antibody conjugated with any of various molecules, such as polyethylene glycol (PEG). The term "antibody" as used herein also encompasses these modified antibodies. Such a modified antibody can be prepared by chemically modifying an antibody obtained as above. Methods of antibody modification have already been established in the art.

35 [0054] The antibody used in the present invention may be a bispecific antibody. A bispecific antibody may have antigen-binding sites that recognize different epitopes on the glycan 3 molecule, or one antigen-binding site may recognize glycan 3 and the other antigen-binding site may recognize a cytotoxic substance such as a chemotherapeutic agent or cell-derived toxin. This enables the cytotoxic substance to directly act on a cell expressing glycan 3, thereby specifically damaging tumor cells and suppressing tumor cell proliferation. A bispecific antibody can be prepared by linking the H-L pairs of two types of antibodies. It can also be obtained by fusing hybridomas that produce different monoclonal antibodies to prepare bispecific antibody-producing fused cells. Bispecific antibodies can also be prepared by genetic engineering techniques.

40 [0055] An antibody gene constructed as described above can be expressed and obtained by known methods. In the case of mammalian cells, a gene can be expressed by functionally linking a commonly used effective promoter, the antibody gene to be expressed, and a polyA signal on its 3' downstream side. An example of the promoter/enhancer is human cytomegalovirus immediate early promoter/enhancer.

45 [0056] Examples of other promoter/enhancers that can be used in the present invention for expression of the antibody include, for example, viral promoter/enhancers from retrovirus, polyoma virus, adenovirus, or simian virus 40 (SV40), and promoter/enhancers derived from mammalian cells, such as human elongation factor 1 $\alpha$  (HEF1 $\alpha$ ).

50 [0057] When an SV40 promoter/enhancer is used, gene expression can be readily carried out by the method of Mulligan et al. (*Nature* (1979) 277, 108), and when an HEF1 $\alpha$  promoter/enhancer is used, gene expression can be readily carried out by the method of Mizushima et al. (*Nucleic Acids Res.* (1990) 18, 5322).

55 [0058] In the case of *E. coli*, gene expression can be achieved by functionally linking a commonly used effective promoter, a signal sequence for antibody secretion, and the antibody gene to be expressed. The promoter can be exemplified by the lacZ promoter and the araB promoter. When the lacZ promoter is used, expression can be achieved by the method of Ward et al. (*Nature* (1998) 341, 544-546; *FASEB J.* (1992) 6, 2422-2427), and when the araB promoter is used, expression can be achieved by the method of Better et al. (*Science* (1988) 240, 1041-1043).

[0059] With regard to the signal sequence for antibody secretion, the pelB signal sequence (Lei, S. P. et al. *J. Bacteriol.*

(1987) 169, 4379) may be used when the antibody is produced in the periplasm of *E. coli*. After the antibody produced in the periplasm has been isolated, the antibody structure is appropriately refolded for use.

**[0060]** The replication origin used in the invention includes, for example, those derived from SV40, polyoma virus, adenovirus, or bovine papilloma virus (BPV). In order to amplify the number of gene copies in the host cell system, the expression vector can contain, for example, the aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, *E. coli* xanthine guanine phosphoribosyltransferase (Ecogpt) gene, or dihydrofolate reductase (dhfr) gene as a selection marker.

**[0061]** Any expression system, for example, a eukaryotic cell system or a prokaryotic cell system, can be used to produce the antibody used in the present invention. Examples of eukaryotic cells include animal cells such as an established mammalian cell system or insect cell system and true filamentous fungus cells and yeast cells. Examples of prokaryotic cells include bacterial cells such as cells of *E. coli*.

**[0062]** The antibody used in the present invention is preferably expressed in mammalian cells such as CHO, COS, myeloma, BHK, Vero, or HeLa cells.

**[0063]** The transformed host cell is then cultured in vitro or in vivo to induce production of the antibody of interest. The host cell can be cultured according to known methods. For example, DMEM, MEM, RPMI1640, or IMDM can be used as the culture medium. A serum supplement such as fetal calf serum (FCS) can also be used.

**[0064]** Known means can be used to assay the antigen-binding activity of the antibody used in the present invention (Antibodies A Laboratory Manual. Ed Harlow, David Lane, Cold Spring Harbor Laboratory, 1988) and to measure its ligand-receptor binding inhibitory activity (Harada, A. et al., International Immunology (1993) 5, 681-690).

**[0065]** The antigen-binding activity of the anti-glypican 3 antibody used in the present invention can be measured using ELISA (enzyme-linked immunosorbent assay), EIA (enzyme immunoassay), RIA (radioimmunoassay), or a fluorescent antibody technique. In an enzyme immunoassay, for example, the antigen-binding activity can be evaluated by adding a sample containing the anti-glypican 3 antibody, such as the culture supernatant from anti-glypican 3 antibody-producing cells or the purified antibody, to a plate coated with glypican 3; adding a secondary antibody labeled with an enzyme such as alkaline phosphatase; incubating and then washing the plate; adding an enzyme substrate such as p-nitrophenyl phosphate; and measuring the absorbance. The cytotoxicity of the antibody used in the present invention can be measured by methods known to those skilled in the art.

**[0066]** The ADCC activity can be measured by mixing effector cells, target cells, and anti-glypican 3 antibody and then determining the level of ADCC. For example, mouse splenocytes or monocytes isolated from bone marrow or human peripheral blood can be used as the effector cells. Examples of a target cell include a human established cell line, such as the HuH-7 human hepatoma cell line. The ADCC activity can be measured by preliminarily labeling the target cells with  $^{51}\text{Cr}$ ; adding anti-glypican 3 antibody to the cells; incubating the cells; then adding effector cells at an appropriate ratio with respect to the target cells; collecting the supernatant after incubation; and counting the radioactivity in the supernatant.

**[0067]** The CDC activity can be measured by mixing the aforementioned labeled target cells with anti-glypican 3 antibody; adding complement and incubating; and then counting the radioactivity in the supernatant.

**[0068]** Since an Fc region is generally required for an antibody to exert cytotoxicity, the anti-glypican 3 antibody used in the present invention preferably contains an Fc region in those cases where the cell growth inhibitor of the present invention utilizes the cytotoxic activity of the antibody.

**[0069]** The anti-cancer agent according to the present invention is used to prevent cancer or to prevent the recurrence of cancer after cancer treatment. The anti-cancer agent according to the present invention is particularly preferably used to prevent the recurrence of liver cancer after the resection of liver cancer cells.

**[0070]** The effective dose is selected from the range of 0.001 mg to 1000 mg per kg body weight per administration. Or, a dose can be selected from the range of 0.01 to 100000 mg/body per patient. However, effective dose of the anti-cancer agent according to the present invention containing anti-glypican 3 antibody is not limited to the above described doses.

**[0071]** The anti-cancer agent according to the present invention is generally administered by a parenteral route, for example, by injection (e.g., subcutaneous, intravenous, intramuscular, intraperitoneal) or a transdermal, transmucosal, nasal, or pulmonary route. It may also be administered orally.

**[0072]** With regard to the timing of administration of the anti-cancer agent according to the present invention, it can be administered either before or after the appearance of the clinical symptoms of the disease. According to a particularly preferred embodiment of the present invention, the anti-cancer agent according to the present invention can be administered as adjuvant therapy after the resection of liver cancer cells.

**[0073]** A therapeutic agent comprising the anti-glypican 3 antibody according to the present invention as an active ingredient can be formulated by standard methods (Remington's Pharmaceutical Science, latest edition, Mark Publishing Company, Easton, U.S.A.) and may contain pharmaceutically acceptable carriers and additives.

**[0074]** These carriers and pharmaceutical additives may include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethyl cellulose, sodium poly-

acrylate, sodium alginate, water-soluble dextran, sodium carboxymethyl starch, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerin, glycerin, propylene glycol, vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, and a surfactant acceptable as a pharmaceutical additive.

5 [0075] Such an additive or additives may be appropriately selected according to the dosage form of the therapeutic agent of the present invention, but is not limited to those listed above. For example, an injectable formulation can be prepared by dissolving purified anti-glypican 3 antibody in a solvent such as physiological saline, buffer, or a glucose solution, and then adding an adsorption inhibitor such as Tween 80, Tween 20, gelatin, or human serum albumin to the solution. Or, the freeze-dried agent may be used to prepare a dosage form, which is reconstituted by dissolution prior to use. Examples of the excipient used for freeze-drying include sugar alcohols and saccharides such as mannitol and glucose.

10 [0076] The content of all the patents and references expressly cited in this application are incorporated herein by reference in its entirety. Moreover, the content of the Description and Drawings of Japanese Patent Applications 2004-244273 and 2005-90945, which are the basis for the priority claiming of this application, are incorporated herein by reference in its entirety.

## EXAMPLES

20 [0077] The present invention is described in greater detail by the examples provided below, but these examples do not limit the scope of the present invention.

### Example 1

#### Efficacy of mouse anti-human glypican 3 antibody GC33 in intrahepatic transplant mouse model

25 (1) Measurement of  $\alpha$ -fetoprotein (AFP)

30 [0078] The serum concentration of human AFP was measured as a tumor marker using an ELISA kit for measurement of human AFP (Hope Laboratories). The detection limit by ELISA is about 1 ng/mL, and samples below the detection limit were taken to be 1 ng/mL. To obtain the serum, blood was collected in a Separapit S (Sekisui Chemical) by orbital blood collection, allowed to stand for 15 minutes at room temperature, and then centrifuged for 20 minutes at 1200  $\times$  g.

35 (2) Preparation of intrahepatic transplant mouse model

40 [0079] An intrahepatic transplant mouse model was prepared as follows. HepG2 cells (ATCC) were adjusted to 1  $\times$  10<sup>8</sup>/mL using Hanks medium (Sigma). Under nembutal anesthesia, 50  $\mu$ L of the HepG2 cell suspension (5  $\times$  10<sup>6</sup>/mouse) was injected within the liver capsule of nude mice (Charles River). The serum AFP concentration was measured on day 21 post-transplant, and animals with the range of 10-100 ng/mL were divided into two groups (n = 4). At this time point, the liver cancer cells (tumor mass) were not observed visually. These animals represent a model bearing intrahepatic micrometastasis surviving after liver resection.

45 (3) Antibody administration

45 [0080] The administration formulation was prepared on the day of administration by diluting mouse anti-human glypican 3 antibody GC33 (refer to the Reference Example below) to 0.5 mg/mL in physiological saline (Otsuka Pharmaceutical). The formulation was administered to the aforementioned mouse model at 10 mL/kg through the tail vein on the 21st and 28th days following tumor transplantation. The physiological saline vehicle was administered in the same manner for the negative control.

50 (4) Evaluation of antitumor effect

55 [0081] The antitumor effect was evaluated based on the AFP concentration on the 35th day post-tumor transplantation. As shown in Figure 1, the AFP concentration on the 35th day post-tumor transplant was lower for the group receiving GC33 than for the group receiving vehicle, indicating that the antibody of the invention has an anti-tumor effect.

[0082] As shown in the above results, GC33 exhibited an antitumor effect in the intrahepatic transplant model, suggesting that the antibody of the invention is useful in adjuvant therapy.

Example 2Test of early administration of mouse anti-human glycan 3 antibody GC33 in intrahepatic transplant mouse model5 (1) Measurement of  $\alpha$ -fetoprotein (AFP)

[0083] The serum concentration of human AFP was measured as a tumor marker using an ELISA kit for measurement of human AFP (Hope Laboratories). The detection limit by ELISA is about 1 ng/mL, and samples below the detection limit were taken to be 1 ng/mL. To obtain the serum, blood was collected in a Separapit S (Sekisui Chemical) by orbital blood collection, allowed to stand for 15 minutes at room temperature, and then centrifuged for 20 minutes at 1200  $\times$  g.

## 10 (2) Preparation of intrahepatic transplant mouse model

[0084] An intrahepatic transplant mouse model was prepared as follows. HepG2 cells (ATCC) were adjusted to  $1 \times 10^8$ /mL using Hanks medium (Sigma). Under nembutal anesthesia, 50  $\mu$ L of the HepG2 cell suspension ( $5 \times 10^6$ /mouse) was injected within the liver capsule of nude mice (Charles River). On the day following transplantation, the animals were randomly divided into two groups ( $n = 10$ ). While HepG2 was present in the mouse liver on the day following transplantation, human AFP was not detected in the mouse serum at that time. These animals represent a clinically closer model bearing intrahepatic micrometastasis remaining after liver resection.

## 20 (3) Antibody administration

[0085] The administration formulation was prepared on the day of administration by diluting mouse anti-human glycan 3 antibody GC33 (refer to the Reference Example below) to 0.5 mg/mL in physiological saline (Otsuka Pharmaceutical). The formulation was administered to the aforementioned mouse model at 10 mL/kg through the tail vein on the day following tumor transplantation and on the 7th day following tumor transplantation. The physiological saline vehicle was administered in the same manner for the negative control.

## 30 (4) Evaluation of antitumor effect

[0086] The antitumor effect was evaluated based on the AFP concentration on the 15th and 40th day post-tumor transplantation. As shown in Figure 2, an increase in the AFP concentration was not seen for either time point in the group receiving GC33. In contrast, an increase in AFP concentration was observed in the group receiving the vehicle.

[0087] As shown in the above results, tumor growth was also inhibited in a model in which liver cancer cells were intrahepatically transplanted, by administrating mouse anti-human glycan 3 antibody GC33 from an early stage where AFP was not detected, indicating that the antibody of the present invention is useful in adjuvant therapy.

Reference Example40 Preparation of mouse anti-human glycan 3 antibody GC33

[0088] Using as immunogen a fusion protein (GC-3) from GST and the peptide from the alanine at position 524 to the lysine at position 563 of glycan 3, three Balb/c mice (purchased from Charles River Japan) and three MRL/lpr mice were immunized. In the initial immunization, the emulsion prepared with FCA and adjusted to 100  $\mu$ g GC-3 per head was administered subcutaneously. After two weeks, an emulsion prepared with FIA and adjusted to 50  $\mu$ g per head was administered subcutaneously. After the fifth immunization, 50  $\mu$ g per head was injected into the tail vein of all the mice as a final immunization, and then cell fusion was carried out. The hybridoma was screened by ELISA using immunoplates on which soluble GPC3 core protein (the hydrophobic region from amino acid 564 to 580 on the C-terminal side are deleted) had been immobilized. Positive clones were selected and monocloned by the limiting dilution method. In this way, the antibody GC33 exhibiting a strong binding activity for GPC3 was obtained. The amino acid sequence of the H-chain and L-chain variable regions of GC33 is shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively.

INDUSTRIAL APPLICABILITY

55 [0089] The anti-cancer agent according to the present invention is useful for preventing cancer and for preventing the recurrence of cancer.

## SEQUENCE LISTING

5                   <110> Chugai Seiyaku Kabushiki Kaisha  
 10                  <120> Adjuvant Therapy using Anti-Glypican 3 Antibodies  
 15                  <130> PCG-9010WO  
 20                  <150> JP 2005-90945  
 25                  <151> 2005-03-28  
 30                  <150> JP 2004-244273  
 35                  <151> 2004-08-24  
 40                  <160> 4  
 45                  <170> PatentIn version 3.1  
 50                  <210> 1  
 55                  <211> 1743  
 60                  <212> DNA  
 65                  <213> homo sapiens  
 70                  <400> 1  
 75                  atggccggga ccgtgcgcac cgcggtgttgc tggtggcga tgctgtcag ctggacttc   60  
 80                  ccggggacagg cgcaaaaaaa gcccggccg ccggacgcca cctgtcacca agtccgctcc   120  
 85                  ttcttccaga gactgcagcc cggactcaag tgggtgcccag aaactcccgat gccaggatca   180  
 90                  gatttgcaag tatgtctccc taagggccca acatgctgct caagaaagat ggaagaaaaaa   240  
 95                  taccaactaa cagcacgatt gaacatggaa cagctgcttc agtctgcaag tatggagctc   300  
 100                 aagttcttaa ttattcagaa tgctgcggtt ttccaagagg cctttgaaat tttttttcgc   360  
 105                 catgccaaga actacaccaa tgccatgttc aagaacaact acccaaggct gactccacaa   420  
 110                 gcctttgagt ttgtgggtga atttttcaca gatgtgtctc tctacatctt gggttctgac   480  
 115                 atcaatgttag atgacatggt caatgaattt tttgacagcc tttttccagt catctataacc   540  
 120                 cagctaatga acccaggcct gcctgattca gccttggaca tcaatgagtg cctccgagga   600  
 125                 gcaagacgtg acctgaaatg atttggaaat ttcccaagc ttattatgac ccaggttcc   660  
 130                 aagtcaactgc aagtcaactgc gatcttcattt caggctctga atcttggaaat tgaagtgtac   720  
 135                 aacacaactg atcacctgaa gttcagtaag gactgtggcc gaatgctcac cagaatgtgg   780  
 140                 tactgctctt actgccagg actgatgtatg gttaaaccct gtggcggtta ctgcaatgtg   840  
 145                 gtcatgcaag gctgtatggc aggtgtggtg gagattgaca agtactggag agaatacatt   900  
 150                 ctgtcccttg aagaacttgtt gaatggcatg tacagaatct atgacatggaa gaacgtactg   960  
 155                 cttggctctt tttcaacaat ccatgattct atccagttatg tccagaagaa tgcaggaaag   1020  
 160                 ctgaccacca ctattggcaa gttatgtgtcc cattctcaac aacgccaata tagatctgct   1080  
 165                 tattatcctt aagatctttt tattgacaag aaagtattaa aagttgctca tgtagaacat   1140  
 170                 gaagaaacctt tatccagccg aagaaggaa ctaattcaga agttgaagtc ttcatcagc   1200

|    |   |              |            |             |            |             |      |
|----|---|--------------|------------|-------------|------------|-------------|------|
|    | ttctatagtg  | ctttgcctgg   | ctacatctgc | agccatagcc  | ctgtggcgga | aaacgacacc  | 1260 |
| 5  | ctttgcctgga   | atggacaaga   | actcgtggag | agatacagcc  | aaaaggcagc | aaggaatgga  | 1320 |
|    | atgaaaaacc  | agttcaatct   | ccatgagctg | aaaatgaagg  | gccctgagcc | agtggtcagt  | 1380 |
| 10 | caaattattg  | acaaactgaa   | gcacattaac | cagctcctga  | gaaccatgtc | tatgccccaaa | 1440 |
|    | ggtagagttc  | tggataaaaa   | cctggatgag | gaagggtttg  | aaagtggaga | ctgcggtgat  | 1500 |
| 15 | gatgaagatg  | agtgcattgg   | aggcctctgg | gatggaatgta | taaaagtgaa | gaatcagtc   | 1560 |
|    | cgcttccttg  | cagaactggc   | ctatgatctg | gatgtggatg  | atgcgcctgg | aaacagttag  | 1620 |
|    | caggcaactc  | cgaaggacaa   | cgagataagc | acctttcaca  | acctcgggaa | cgttcattcc  | 1680 |
|    | ccgctgaagc  | ttctcaccag   | catggccatc | tcggtggtgt  | gcttcttctt | ccggggcac   | 1740 |
|    | tga   |              |            |             |            |             | 1743 |
|    | <210>   | 2            |            |             |            |             |      |
| 20 | <211>   | 580          |            |             |            |             |      |
|    | <212>   | PRT          |            |             |            |             |      |
|    | <213>   | homo sapiens |            |             |            |             |      |
|    | <400>   | 2            |            |             |            |             |      |
| 25 | Met Ala Gly Thr Val Arg Thr Ala Cys Leu Val Val Ala Met Leu Leu |              |            |             |            |             |      |
|    | 1   | 5            | 10         |             |            | 15          |      |
|    | Ser Leu Asp Phe Pro Gly Gln Ala Gln Pro Pro Pro Pro Pro Pro Asp |              |            |             |            |             |      |
| 30 | 20  | 25           | 30         |             |            |             |      |
|    | Ala Thr Cys His Gln Val Arg Ser Phe Phe Gln Arg Leu Gln Pro Gly |              |            |             |            |             |      |
|    | 35  | 40           | 45         |             |            |             |      |
|    | Leu Lys Trp Val Pro Glu Thr Pro Val Pro Gly Ser Asp Leu Gln Val |              |            |             |            |             |      |
| 35 | 50  | 55           | 60         |             |            |             |      |
|    | Cys Leu Pro Lys Gly Pro Thr Cys Cys Ser Arg Lys Met Glu Glu Lys |              |            |             |            |             |      |
|    | 65  | 70           | 75         |             |            | 80          |      |
| 40 | Tyr Gln Leu Thr Ala Arg Leu Asn Met Glu Gln Leu Leu Gln Ser Ala |              |            |             |            |             |      |
|    | 85  | 90           | 95         |             |            |             |      |
|    | Ser Met Glu Leu Lys Phe Leu Ile Ile Gln Asn Ala Ala Val Phe Gln |              |            |             |            |             |      |
| 45 | 100   | 105          | 110        |             |            |             |      |
|    | Glu Ala Phe Glu Ile Val Val Arg His Ala Lys Asn Tyr Thr Asn Ala |              |            |             |            |             |      |
|    | 115   | 120          | 125        |             |            |             |      |
|    | Met Phe Lys Asn Asn Tyr Pro Ser Leu Thr Pro Gln Ala Phe Glu Phe |              |            |             |            |             |      |
| 50 | 130   | 135          | 140        |             |            |             |      |
|    | Val Gly Glu Phe Phe Thr Asp Val Ser Leu Tyr Ile Leu Gly Ser Asp |              |            |             |            |             |      |
|    | 145   | 150          | 155        |             |            | 160         |      |
| 55 | Ile Asn Val Asp Asp Met Val Asn Glu Leu Phe Asp Ser Leu Phe Pro |              |            |             |            |             |      |

|    |   |     |     |
|----|---|-----|-----|
|    | 165   | 170 | 175 |
| 5  | Val Ile Tyr Thr Gln Leu Met Asn Pro Gly Leu Pro Asp Ser Ala Leu |     |     |
|    | 180   | 185 | 190 |
|    | Asp Ile Asn Glu Cys Leu Arg Gly Ala Arg Arg Asp Leu Lys Val Phe |     |     |
|    | 195   | 200 | 205 |
| 10 | Gly Asn Phe Pro Lys Leu Ile Met Thr Gln Val Ser Lys Ser Leu Gln |     |     |
|    | 210   | 215 | 220 |
|    | Val Thr Arg Ile Phe Leu Gln Ala Leu Asn Leu Gly Ile Glu Val Ile |     |     |
|    | 225   | 230 | 235 |
| 15 | Asn Thr Thr Asp His Leu Lys Phe Ser Lys Asp Cys Gly Arg Met Leu |     |     |
|    | 245   | 250 | 255 |
|    | Thr Arg Met Trp Tyr Cys Ser Tyr Cys Gln Gly Leu Met Met Val Lys |     |     |
| 20 | 260   | 265 | 270 |
|    | Pro Cys Gly Gly Tyr Cys Asn Val Val Met Gln Gly Cys Met Ala Gly |     |     |
|    | 275   | 280 | 285 |
| 25 | Val Val Glu Ile Asp Lys Tyr Trp Arg Glu Tyr Ile Leu Ser Leu Glu |     |     |
|    | 290   | 295 | 300 |
|    | Glu Leu Val Asn Gly Met Tyr Arg Ile Tyr Asp Met Glu Asn Val Leu |     |     |
|    | 305   | 310 | 315 |
| 30 | Leu Gly Leu Phe Ser Thr Ile His Asp Ser Ile Gln Tyr Val Gln Lys |     |     |
|    | 325   | 330 | 335 |
|    | Asn Ala Gly Lys Leu Thr Thr Ile Gly Lys Leu Cys Ala His Ser     |     |     |
| 35 | 340   | 345 | 350 |
|    | Gln Gln Arg Gln Tyr Arg Ser Ala Tyr Tyr Pro Glu Asp Leu Phe Ile |     |     |
|    | 355   | 360 | 365 |
| 40 | Asp Lys Lys Val Leu Lys Val Ala His Val Glu His Glu Glu Thr Leu |     |     |
|    | 370   | 375 | 380 |
|    | Ser Ser Arg Arg Arg Glu Leu Ile Gln Lys Leu Lys Ser Phe Ile Ser |     |     |
|    | 385   | 390 | 395 |
| 45 | Phe Tyr Ser Ala Leu Pro Gly Tyr Ile Cys Ser His Ser Pro Val Ala |     |     |
|    | 405   | 410 | 415 |
|    | Glu Asn Asp Thr Leu Cys Trp Asn Gly Gln Glu Leu Val Glu Arg Tyr |     |     |
| 50 | 420   | 425 | 430 |
|    | Ser Gln Lys Ala Ala Arg Asn Gly Met Lys Asn Gln Phe Asn Leu His |     |     |
|    | 435   | 440 | 445 |
| 55 | Glu Leu Lys Met Lys Gly Pro Glu Pro Val Val Ser Gln Ile Ile Asp |     |     |

|    |   |     |     |
|----|---|-----|-----|
|    | 450   | 455 | 460 |
| 5  | Lys Leu Lys His Ile Asn Gln Leu Leu Arg Thr Met Ser Met Pro Lys |     |     |
|    | 465   | 470 | 475 |
|    | Gly Arg Val Leu Asp Lys Asn Leu Asp Glu Glu Gly Phe Glu Ser Gly |     |     |
|    | 485   | 490 | 495 |
| 10 | Asp Cys Gly Asp Asp Glu Asp Cys Ile Gly Gly Ser Gly Asp Gly     |     |     |
|    | 500   | 505 | 510 |
|    | Met Ile Lys Val Lys Asn Gln Leu Arg Phe Leu Ala Glu Leu Ala Tyr |     |     |
| 15 | 515   | 520 | 525 |
|    | Asp Leu Asp Val Asp Asp Ala Pro Gly Asn Ser Gln Gln Ala Thr Pro |     |     |
|    | 530   | 535 | 540 |
| 20 | Lys Asp Asn Glu Ile Ser Thr Phe His Asn Leu Gly Asn Val His Ser |     |     |
|    | 545   | 550 | 555 |
|    | Pro Leu Lys Leu Leu Thr Ser Met Ala Ile Ser Val Val Cys Phe Phe |     |     |
|    | 565   | 570 | 575 |
| 25 | Phe Leu Val His   |     |     |
|    | 580   |     |     |
|    | <210> 3   |     |     |
| 30 | <211> 115   |     |     |
|    | <212> PRT   |     |     |
|    | <213> Mus musculus  |     |     |
|    | <400> 3   |     |     |
| 35 | Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala |     |     |
|    | 1   | 5   | 10  |
|    | Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr |     |     |
| 40 | 20  | 25  | 30  |
|    | Glu Met His Trp Val Lys Gln Thr Pro Val His Gly Leu Lys Trp Ile |     |     |
|    | 35  | 40  | 45  |
| 45 | Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe |     |     |
|    | 50  | 55  | 60  |
|    | Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr |     |     |
| 50 | 65  | 70  | 75  |
|    | Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys |     |     |
|    | 85  | 90  | 95  |
|    | Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr |     |     |
| 55 | 100   | 105 | 110 |

5                   Val Ser Ala  
10                   115  
15                   <210> 4  
20                   <211> 112  
25                   <212> PRT  
30                   <213> *Mus musculus*  
35                   <400> 4  
40                   Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly  
45                   1               5               10               15  
50                   Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser  
55                   20               25               30  
60                   Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
65                   35               40               45  
70                   Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro  
75                   50               55               60  
80                   Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
85                   65               70               75               80  
90                   Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn  
95                   85               90               95  
100                  Thr His Val Pro Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys  
105                  100               105               110

40                   Claims

1. An anti-cancer agent comprising anti-glypican 3 antibody, wherein said anti-cancer agent is administered after a cancer treatment.
2. The anti-cancer agent according to claim 1, wherein after a cancer treatment is after a treatment for liver cancer.
3. The anti-cancer agent according to claim 2, wherein the treatment for liver cancer is a resection of liver cancer cells.
4. The anti-cancer agent according to claim 2 or 3, wherein the anti-cancer agent is administered if glypican 3 is expressed in the resected liver cancer cells.
5. The anti-cancer agent according to any of claims 1 to 4, wherein the antibody is a monoclonal antibody.
6. A method of preventing recurrence of cancer in a patient after a cancer treatment comprising administering to the patient an anti-cancer agent comprising anti-glypican 3 antibody.
7. The method according to claim 6, wherein after a cancer treatment is after a treatment for liver cancer.

8. The method according to claim 7, wherein the treatment for liver cancer is a resection of liver cancer cells.
9. The method according to claim 7 or 8, wherein glypican 3 is expressed in the resected liver cells.
- 5      10. The method according to any of claims 6 to 9, wherein the antibody is a monoclonal antibody.

10

15

20

25

30

35

40

45

50

55




FIG. 1




FIG. 2

| INTERNATIONAL SEARCH REPORT   |   | International application No.<br>PCT/JP2005/015607                                |
|---|---|---|
| A. CLASSIFICATION OF SUBJECT MATTER<br>Int. Cl <sup>7</sup> A61K39/395, A61P35/00   |   |   |
| According to International Patent Classification (IPC) or to both national classification and IPC   |   |   |
| B. FIELDS SEARCHED<br>Minimum documentation searched (classification system followed by classification symbols)<br>Int. Cl <sup>7</sup> A61K39/395  |   |   |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br>Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2005<br>Kokai Jitsuyo Shinan Koho 1971-2005 Toroku Jitsuyo Shinan Koho 1994-2005   |   |   |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>REGISTRY/CA/MEDLINE/EMBASE/BIOSIS (STN), JSTPlus/JMEDPlus (JOIS)  |   |   |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT  |   |   |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages                            | Relevant to claim No.   |
| X<br>Y  | WO 2003/883 A1 (Chugai Pharmaceutical Co., Ltd.),<br>03 January, 2003 (03.01.03),<br>Claims<br>& EP 141118 A1 | 1, 2, 5<br>3, 4   |
| Y   | Yoshiyuki YAMAGUCHI et al., "Gan Biotherapy no Kyo Ashita", Biotherapy, 1999, Vol.13, No.7, pages 747 to 753  | 1-5   |
| A   | WO 2004/18667 A1 (Kirin Brewery Co., Ltd.),<br>04 March, 2004 (04.03.04),<br>Full text<br>(Family: none)      | 1-5   |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.  |   |   |
| <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p> |   |   |
| Date of the actual completion of the international search<br>13 September, 2005 (13.09.05)  |   | Date of mailing of the international search report<br>04 October, 2005 (04.10.05) |
| Name and mailing address of the ISA/<br>Japanese Patent Office  |   | Authorized officer  |
| Facsimile No.   |   | Telephone No.   |

| INTERNATIONAL SEARCH REPORT                           |   | International application No.<br>PCT/JP2005/015607 |
|---|---|--|
| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |   |  |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.                              |
| A   | SUNG, Y.K. et al., Glypican-3 is overexpressed in human hepatocellular carcinoma, <i>Cancer Sci.</i> , 2003, Vol.94, No.3, pages 259 to 262 | 1-5  |

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2005/015607

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 6 - 10  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claims 6 to 10 pertain to methods for treatment of the human body by therapy and thus relate to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2) (a) (i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 0300883 A [0005]
- JP 1059878 A [0030]
- WO 9425585 A [0030]
- WO 9312227 A [0030]
- WO 9203918 A [0030]
- WO 9402602 A [0030]
- WO 9411523 A [0039]
- EP 125023 A [0043]
- WO 9602576 A [0043]
- WO 9813388 A [0044]
- JP 2004244273 A [0076]
- JP 2005090945 A [0076]

## Non-patent literature cited in the description

- FILMUS, J. ; CHURCH, J.G. ; BUICK, R.N. *Mol. Cell. Biol.*, 1988, vol. 8, 4243-4249 [0004]
- FILMUS, J. ; SHI, W. ; WONG, Z.-M. ; WONG, M.J. *Biochem. J.*, 1995, vol. 311, 561-565 [0004]
- HERMANN LAGE et al. *Gene*, 1997, vol. 188, 151-156 [0004]
- PILIA, G. et al. *Nat. Genet.*, 1996, vol. 12, 241-247 [0004]
- HEY-CHI HSU et al. *Cancer Research*, 1997, vol. 57, 5179-5184 [0005]
- LAGE, H. et al. *Gene*, 1997, vol. 188, 151-156 [0019]
- *J. Immunol.*, 1979, vol. 123, 1548-1550 [0024]
- *Current Topics in Microbiology and Immunology*, 1978, vol. 81, 1-7 [0024]
- KOHLER, G. ; MILSTEIN, C. *Eur. J. Immunol.*, 1976, vol. 6, 511-519 [0024]
- MARGULIES, D. H. et al. *Cell*, 1976, vol. 8, 405-415 [0024]
- SHULMAN, M. et al. *Nature*, 1978, vol. 276, 269-270 [0024]
- DE ST. GROTH, S. F. et al. *J. Immunol. Methods*, 1980, vol. 35, 1-21 [0024]
- TROWBRIDGE, I. S. *J. Exp. Med.*, 1978, vol. 148, 313-323 [0024]
- GALFRE, G. et al. *Nature*, 1979, vol. 277, 131-133 [0024]
- KOHLER, G. ; MILSTEIN, C. *Methods Enzymol.*, 1981, vol. 73, 3-46 [0025]
- VANDAMME, A. M. et al. *Eur. J. Biochem.*, 1990, vol. 192, 767-775 [0033]
- CHIRGWIN, J. M. et al. *Biochemistry*, 1979, vol. 18, 5294-5299 [0034]
- CHOMCZYNSKI, P. et al. *Anal. Biochem.*, 1987, vol. 162, 156-159 [0034]
- FROHMAN, M. A. et al. *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 8998-9002 [0035]
- BELYAVSKY, A. et al. *Nucleic Acids Res.*, 1989, vol. 17, 2919-2932 [0035]
- EBERT, K. M. et al. *Bio/Technology*, 1994, vol. 12, 699-702 [0040]
- SATO, K. et al. *Cancer Res.*, 1993, vol. 53, 851-856 [0045]
- CO, M.S. et al. *J. Immunol.*, 1994, vol. 152, 2968-2976 [0048]
- BETTER, M. ; HORWITZ, A. H. *Methods in Enzymology*. Academic Press, Inc, 1989, vol. 178, 476-496 [0048]
- PLUECKTHUN, A. ; SKERRA, A. *Methods in Enzymology*. Academic Press, Inc, 1989, vol. 178, 476-496 [0048]
- LAMOYI, E. *Methods in Enzymology*, 1989, vol. 121, 652-663 [0048]
- ROUSSEAU, J. et al. *Methods in Enzymology*, 1989, vol. 121, 663-669 [0048]
- BIRD, R. E. et al. *TIBTECH*, 1991, vol. 9, 132-137 [0048]
- HUSTON, J. S. et al. *Proc. Natl. Acad. Sci. U.S.A.*, 1988, vol. 85, 5879-5883 [0049]
- MULLIGAN et al. *Nature*, 1979, vol. 277, 108 [0057]
- MIZUSHIMA et al. *Nucleic Acids Res.*, 1990, vol. 18, 5322 [0057]
- WARD et al. *Nature*, 1998, vol. 341, 544-546 [0058]
- FASEB J., 1992, vol. 6, 2422-2427 [0058]
- BETTER et al. *Science*, 1988, vol. 240, 1041-1043 [0058]
- LEI, S. P. et al. *J. Bacteriol.*, 1987, vol. 169, 4379 [0059]
- Antibodies A Laboratory Manual. Cold Spring Harbor Laboratory, 1988 [0064]
- HARADA, A. et al. *International Immunology*, 1993, vol. 5, 681-690 [0064]
- Remington's Pharmaceutical Science. Mark Publishing Company [0073]